Tertiary aminoalcohol choline analog and putative acetylcholine precursor with antioxidant and membrane-active properties
A naturally occurring dimethylated ethanolamine historically developed as the prescription drug Deaner for pediatric behavioral disorders, subsequently investigated for tardive dyskinesia, senile dementia, and dermatological aging, and now positioned as a dietary supplement cholinergic agent distinguished from conventional choline sources by competitive blood-brain barrier transport affinity and membrane phospholipid incorporation.
Abstract
Dimethylaminoethanol (DMAE), also known as deanol or 2-(dimethylamino)ethanol, is a tertiary aminoalcohol endogenous to human brain tissue and present at nutritionally relevant concentrations in certain marine fish species (sardines, anchovies, salmon). Structurally, DMAE differs from choline (2-hydroxyethyltrimethylammonium) by the absence of one N-methyl group, a distinction that confers higher lipophilicity, competitive affinity for the choline carrier at the blood-brain barrier (inhibition constant approximately 159 micromolar versus Michaelis constant approximately 442 micromolar for choline), and the capacity for incorporation into membrane phospholipids as phosphatidyldimethylaminoethanol (PDMAE) in place of phosphatidylcholine. The drug was voluntarily withdrawn in 1983 when the manufacturer elected not to submit the contemporary efficacy data required by evolving FDA regulatory standards, rather than for safety concerns. Subsequent clinical investigation extended to tardive dyskinesia, senile dementia, and dermatological applications. In tardive dyskinesia, a Cochrane systematic review and meta-analysis of randomized controlled trials concluded that DMAE was no more effective than placebo and was associated with an increased risk of adverse outcomes [1]. In senile dementia, open-label and small controlled trials produced modest behavioral improvements without measurable cognitive or memory enhancement [2]. The dermatological evidence base is more favorable: a randomized, double-blind, placebo-controlled trial of 3 percent DMAE facial gel applied daily for 16 weeks demonstrated statistically significant improvements in forehead lines, periorbital fine wrinkles, lip shape, and overall facial skin appearance, with effects maintained on cessation and safety confirmed through 12 months of open-label extension [3]. The pharmacological mechanism remains incompletely resolved. The classical hypothesis that DMAE serves as a direct acetylcholine precursor through sequential methylation to choline and subsequent acetylation by choline acetyltransferase has been challenged by disposition studies demonstrating that DMAE is not metabolized to choline in vivo and that its principal urinary metabolite is DMAE N-oxide [4]. Alternative mechanistic proposals include competitive inhibition of choline reuptake at the blood-brain barrier (thereby elevating peripheral choline concentrations), direct incorporation into neuronal membrane phospholipids as PDMAE with consequent alteration of membrane fluidity and receptor function, free radical scavenging activity against hydroxyl and lipid radicals confirmed by electron paramagnetic resonance spectroscopy [5], and anti-inflammatory activity through suppression of interleukin-2 and interleukin-6 secretion. DMAE is also the active moiety released by hydrolysis of centrophenoxine (meclofenoxate), a nootropic drug marketed in several jurisdictions for age-related cognitive decline, in which the para-chlorophenoxyacetic acid ester linkage enhances oral bioavailability and central nervous system penetration. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.